Building on the findings from IL-6 and IL-10 studies, future research should explore whether IL-27 activates gut immune and endocrine pathways to promote GLP-1 secretion, thereby improving insulin resistance and alleviating glucose and lipid metabolism disorders associated with obesity. Here, GLP1R is linked to Insulin resistance.